C1 inhibitor (Cinryze®) 500 units powder and solvent for solution for injection
All Wales Medicines Strategy Group (AWMSG)
Record ID 32013000334
English
Authors' recommendations:
C1 inhibitor (Cinryze®) is recommended as an option for use within NHS Wales for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema, and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema who are intolerant to or insufficiently protected by oral prevention treatments or who are inadequately managed with repeated acute treatment.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
http://www.wales.nhs.uk/sites3/Documents/371/C1%20inhibitor%20%28Cinryze%29%20FAR.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Complement C1 Inactivator Proteins
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.